<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934934</url>
  </required_header>
  <id_info>
    <org_study_id>CANTREAT</org_study_id>
    <nct_id>NCT00934934</nct_id>
  </id_info>
  <brief_title>Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment</brief_title>
  <acronym>CANTREAT</acronym>
  <official_title>Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daren K. Heyland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the effect of treating Candida spp. isolated&#xD;
      in the respiratory tract secretions of patients with a clinical suspicion of ventilator&#xD;
      associated pneumonia (VAP) on clinical outcomes will be feasible and supported by biomarker&#xD;
      data obtained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Candida spp. is commonly retrieved from microbiologic specimens of ICU patients with&#xD;
      suspected VAP. It has been associated with increased systemic inflammation and worse clinical&#xD;
      outcomes. This association may be due to the propensity for Candida to colonize those who are&#xD;
      sicker, who have increased levels of systemic inflammation and worse clinical outcomes.&#xD;
      However, an alternate possibility is that Candida is more than a colonizer and is responsible&#xD;
      for the clinical and biochemical features observed. The only way to clarify the pathogenic&#xD;
      role of Candida from this patient population is to treat the organism and see if patients&#xD;
      improve compared to an untreated group. The purpose of this research program is to conduct&#xD;
      such a study to determine if Candida in respiratory tract secretions should be routinely&#xD;
      treated in critically ill patients. Since a definitive randomized controlled trial designed&#xD;
      to demonstrate a reduction in mortality would be large, require the commitment of large&#xD;
      amount of resources including both time and money, the investigators propose to first conduct&#xD;
      a small pilot feasibility study.&#xD;
&#xD;
      Eligible patients will be randomized to receive antifungal treatment with anidulafungin or&#xD;
      placebo. Following enrollment, study treatment (or placebo) will be started as soon as&#xD;
      possible. When the Candida or yeast organisms have been speciated and/or a susceptibility&#xD;
      profile is known, the study medication will be adjusted based on susceptibility patterns. The&#xD;
      investigators propose to treat with antifungal therapy for a total of 14 days.&#xD;
&#xD;
      Patients will be followed daily for their entire stay in ICU or till day 28, whichever comes&#xD;
      first. For patients discharged from the ICU to the ward, they will be followed until study&#xD;
      treatment is complete (i.e. day 14). Mortality will be determined for the ICU stay, hospital&#xD;
      stay and at 90 days. The investigators will record admission and discharge dates to ICU, step&#xD;
      down units, and to hospital.&#xD;
&#xD;
      All patients will have 13 mL of blood/day drawn at baseline, day 3, day 8 and at the end of&#xD;
      the treatment period on day 14 (or last day of treatment). The samples will be prepared on&#xD;
      site and shipped to a central lab for processing. The investigators will use the blood&#xD;
      specimens to measure markers of inflammation (C-reactive protein, Procalcitonin, and&#xD;
      Interleukin-6 and others as determined by the investigators), markers of candida presence&#xD;
      (b-glucan and other potential future markers) and markers of immune dysfunction (to be&#xD;
      determined by investigators).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Recruitment Rate</measure>
    <time_frame>32 months</time_frame>
    <description>Overall recruitment rate per site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Stay in ICU</measure>
    <time_frame>28 days</time_frame>
    <description>Measure of the duration of participant stay in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days in ICU free of ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days free of ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic Free Days 28-day Post Randomization</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days free of antibiotic use within the first 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>90 days</time_frame>
    <description>Measure of the duration of the participant's hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(SOFA) Post Randomization</measure>
    <time_frame>post randomization</time_frame>
    <description>Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Procalcitonin</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-glucan Levels</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <condition>Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will serve as the placebo solution since the active comparator is clear and colourless.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antifungal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive a dose daily for a total of 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anidulafungin</intervention_name>
    <description>TBA</description>
    <arm_group_label>Antifungal</arm_group_label>
    <other_name>TBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients (&gt;18 years old)&#xD;
&#xD;
          2. In the ICU &gt; 48 hours&#xD;
&#xD;
          3. Mechanically ventilated (&gt;48 hours)&#xD;
&#xD;
          4. Grow a Candida spp. on respiratory tract secretion culture (either by Bronchoalveolar&#xD;
             Lavage or Endotracheal Aspirate) taken on or between 48 hours before or after the day&#xD;
             of their suspicion of respiratory tract infection.&#xD;
&#xD;
          5. Develop a clinical suspicion of respiratory tract infection while ventilated as&#xD;
             defined by the following criteria (as defined previously in our VAP trial)5:&#xD;
&#xD;
               -  The presence of new, worsening or persistent radiographic features suggestive of&#xD;
                  pneumonia without another obvious cause AND&#xD;
&#xD;
               -  The presence of any two of the following:&#xD;
&#xD;
                    -  Fever &gt; 38C (core temperature)&#xD;
&#xD;
                    -  Leukocytosis (&gt;11.0 x109/L) or neutropenia (&lt;3.5 x109/L)&#xD;
&#xD;
                    -  Purulent endotracheal aspirates or change in character of aspirates&#xD;
&#xD;
                    -  Isolation of pathogenic bacteria from endotracheal aspirates&#xD;
&#xD;
                    -  Increasing oxygen requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients not expected to be in ICU for more than 72 hours (due to imminent death,&#xD;
             withdrawal of aggressive care or discharge).&#xD;
&#xD;
          2. Patients with Candida spp. in the blood or another sterile body site.&#xD;
&#xD;
          3. Patients colonized at other non-pulmonary body site(s) with Candida.&#xD;
&#xD;
          4. Already being treated with antifungal drugs (because of documented fungal infection,&#xD;
             pre-emptive therapy, or prophylaxis).&#xD;
&#xD;
          5. Allergy to study drugs (Fluconazole or the Echinocandin on formulary at treating&#xD;
             institution).&#xD;
&#xD;
          6. Immunocompromised patients (post-organ transplantation, Acquired Immunodeficiency&#xD;
             Syndrome [AIDS], neutropenia [&lt;1000 absolute neutrophils], corticosteroids [&gt;20&#xD;
             mgs/day of prednisone or equivalent for more than 6 months]). These patients are&#xD;
             excluded since Candida may be more invasive and these patients are much more likely to&#xD;
             require systemic antifungal therapy.&#xD;
&#xD;
          7. Patients with fulminant liver failure or end stage liver disease (Child's Class C).&#xD;
&#xD;
          8. Women who are pregnant or lactating.&#xD;
&#xD;
          9. Enrollment in industry sponsored interventional trial (co-enrollment in other academic&#xD;
             studies would be allowed with the proviso that there was no potential interaction&#xD;
             between the protocols).&#xD;
&#xD;
         10. Prior randomization in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daren Heyland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Evaluation Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur do Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Enfant-Jesus</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005 Oct;33(10):2184-93. Review.</citation>
    <PMID>16215368</PMID>
  </reference>
  <reference>
    <citation>Muscedere JG, Martin CM, Heyland DK. The impact of ventilator-associated pneumonia on the Canadian health care system. J Crit Care. 2008 Mar;23(1):5-10. doi: 10.1016/j.jcrc.2007.11.012. Review.</citation>
    <PMID>18359415</PMID>
  </reference>
  <reference>
    <citation>Van Saene H., Peric M., De La Cal M., Silvestri L.: Pneumonia during Mechanical Ventilation. Anestiologie a Intenzivni Medicina 2004; 15: 89-100.</citation>
  </reference>
  <reference>
    <citation>Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903. Review.</citation>
    <PMID>11934711</PMID>
  </reference>
  <reference>
    <citation>Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006 Dec 21;355(25):2619-30.</citation>
    <PMID>17182987</PMID>
  </reference>
  <reference>
    <citation>Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008 Mar;36(3):737-44.</citation>
    <PMID>18091545</PMID>
  </reference>
  <reference>
    <citation>Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. J Crit Care. 2008 Mar;23(1):126-37. doi: 10.1016/j.jcrc.2007.11.014.</citation>
    <PMID>18359430</PMID>
  </reference>
  <reference>
    <citation>Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care. 2008 Mar;23(1):138-47. doi: 10.1016/j.jcrc.2007.12.008.</citation>
    <PMID>18359431</PMID>
  </reference>
  <reference>
    <citation>Muscedere JG, McColl C, Shorr A, Jiang X, Marshall J, Heyland DK; Canadian Critical Care Trials Group. Determinants of outcome in patients with a clinical suspicion of ventilator-associated pneumonia. J Crit Care. 2008 Mar;23(1):41-9. doi: 10.1016/j.jcrc.2007.12.007.</citation>
    <PMID>18359420</PMID>
  </reference>
  <reference>
    <citation>Rello J, Esandi ME, Díaz E, Mariscal D, Gallego M, Vallès J. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest. 1998 Jul;114(1):146-9.</citation>
    <PMID>9674461</PMID>
  </reference>
  <reference>
    <citation>el-Ebiary M, Torres A, Fàbregas N, de la Bellacasa JP, González J, Ramirez J, del Baño D, Hernández C, Jiménez de Anta MT. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):583-90.</citation>
    <PMID>9279244</PMID>
  </reference>
  <reference>
    <citation>Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008 Mar 15;46(6):878-85. doi: 10.1086/527382.</citation>
    <PMID>18260755</PMID>
  </reference>
  <reference>
    <citation>Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004 Jul 15;39(2):199-205. Epub 2004 Jun 28.</citation>
    <PMID>15307029</PMID>
  </reference>
  <reference>
    <citation>Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2006 Apr;2(4):e35. Epub 2006 Apr 28.</citation>
    <PMID>16652171</PMID>
  </reference>
  <reference>
    <citation>Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B; Outcomerea Study Group. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest. 2006 Jan;129(1):110-7.</citation>
    <PMID>16424420</PMID>
  </reference>
  <reference>
    <citation>Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care. 2008 Mar;23(1):11-7. doi: 10.1016/j.jcrc.2008.01.005.</citation>
    <PMID>18359416</PMID>
  </reference>
  <reference>
    <citation>Heyland et al, WATTCH database. Observational study of the clinical characteristics and biomarker profiles of 569 critically ill patients. Analysis ongoing.</citation>
  </reference>
  <reference>
    <citation>Williamson D., Martin A., Perreault M., Delisle M., Muscedere J., Rotstein C., Jiang X., Heyland D. Impact of pulmonary Candida colonization on systemic inflammation in the critically ill. Manuscript in preparation.</citation>
  </reference>
  <reference>
    <citation>Magill SS, Swoboda SM, Johnson EA, Merz WG, Pelz RK, Lipsett PA, Hendrix CW. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis. 2006 Aug;55(4):293-301. Epub 2006 May 15. Erratum in: Diagn Microbiol Infect Dis. 2007 Mar;57(3):351.</citation>
    <PMID>16698215</PMID>
  </reference>
  <reference>
    <citation>Müller V, Viemann D, Schmidt M, Endres N, Ludwig S, Leverkus M, Roth J, Goebeler M. Candida albicans triggers activation of distinct signaling pathways to establish a proinflammatory gene expression program in primary human endothelial cells. J Immunol. 2007 Dec 15;179(12):8435-45.</citation>
    <PMID>18056390</PMID>
  </reference>
  <reference>
    <citation>Inoue K, Takano H, Oda T, Yanagisawa R, Tamura H, Ohno N, Adachi Y, Ishibashi K, Yoshikawa T. Candida soluble cell wall beta-D-glucan induces lung inflammation in mice. Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):499-508.</citation>
    <PMID>17880763</PMID>
  </reference>
  <reference>
    <citation>Sakurai T, Ohno N, Yadomae T. Effects of fungal beta-glucan and interferon-gamma on the secretory functions of murine alveolar macrophages. J Leukoc Biol. 1996 Jul;60(1):118-24.</citation>
    <PMID>8699115</PMID>
  </reference>
  <reference>
    <citation>Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di Pompeo C, Dewavrin F, Favory R, Roussel-Delvallez M, Durocher A. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med. 2007 Jan;33(1):137-42. Epub 2006 Nov 8.</citation>
    <PMID>17115135</PMID>
  </reference>
  <reference>
    <citation>Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schüttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002 May;30(5):1015-23.</citation>
    <PMID>12006796</PMID>
  </reference>
  <reference>
    <citation>Williamson D., Albert M., Perreault M., Delisle M., Muscedere J., Rotstein C.Jiang X., Day A. ,Heyland D. Effect of Candida spp. in respiratory tract secretions on systemic inflammation. Submitted to SCCM for Feb. 2009</citation>
  </reference>
  <reference>
    <citation>Presterl E, Lassnigg A, Mueller-Uri P, El-Menyawi I, Graninger W. Cytokines in sepsis due to Candida albicans and in bacterial sepsis. Eur Cytokine Netw. 1999 Sep;10(3):423-30.</citation>
    <PMID>10477399</PMID>
  </reference>
  <reference>
    <citation>Christofilopoulou S, Charvalos E, Petrikkos G. Could procalcitonin be a predictive biological marker in systemic fungal infections?. Study of 14 cases. Eur J Intern Med. 2002 Dec;13(8):493-495.</citation>
    <PMID>12446193</PMID>
  </reference>
  <reference>
    <citation>Reade MC, Angus DC. The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead? Crit Care Med. 2009 Jan;37(1 Suppl):S1-9. doi: 10.1097/CCM.0b013e318192074c.</citation>
    <PMID>19104206</PMID>
  </reference>
  <reference>
    <citation>van Teijlingen E, Hundley V. The importance of pilot studies. Nurs Stand. 2002 Jun 19-25;16(40):33-6. Review.</citation>
    <PMID>12216297</PMID>
  </reference>
  <reference>
    <citation>Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ; McMaster Critical Care Interest Group. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med. 2009 Jan;37(1 Suppl):S69-74. doi: 10.1097/CCM.0b013e3181920e33. Review.</citation>
    <PMID>19104228</PMID>
  </reference>
  <reference>
    <citation>Canadian Institutes of Health Research. Available at: www.cihr.ca Accessed February 9, 2009.</citation>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Daren K. Heyland</investigator_full_name>
    <investigator_title>Director, Clinical Evaluation Research Unit</investigator_title>
  </responsible_party>
  <keyword>Candida</keyword>
  <keyword>ventilator associated pneumonia</keyword>
  <keyword>respiratory tract infection</keyword>
  <keyword>antifungal</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anidulafungin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One pt was mistakenly randomized to intervention without Candida, so was moved to observational group prior to starting treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Saline will serve as the placebo solution since the active comparator is clear and colourless.&#xD;
Normal Saline: Normal Saline</description>
        </group>
        <group group_id="P2">
          <title>Antifungal</title>
          <description>Patient will receive a dose daily for a total of 14 days&#xD;
anidulafungin: TBA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Saline will serve as the placebo solution since the active comparator is clear and colourless.&#xD;
Normal Saline: Normal Saline</description>
        </group>
        <group group_id="B2">
          <title>Antifungal</title>
          <description>Patient will receive a dose daily for a total of 14 days&#xD;
anidulafungin: TBA</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="13.8"/>
                    <measurement group_id="B2" value="57.6" spread="17.1"/>
                    <measurement group_id="B3" value="60.3" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Recruitment Rate</title>
        <description>Overall recruitment rate per site</description>
        <time_frame>32 months</time_frame>
        <population>This outcome measure was pre-specified to be for overall participants not by group. It was a reflection of how recruitment went for this protocol overall not by group.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Recruitment Rate</title>
          <description>Overall recruitment rate per site</description>
          <population>This outcome measure was pre-specified to be for overall participants not by group. It was a reflection of how recruitment went for this protocol overall not by group.</population>
          <units>participants per site /month</units>
          <param>Number</param>
          <units_analyzed>sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Stay in ICU</title>
        <description>Measure of the duration of participant stay in the ICU</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Antifungal</title>
          </group>
        </group_list>
        <measure>
          <title>Duration of Stay in ICU</title>
          <description>Measure of the duration of participant stay in the ICU</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="8" upper_limit="20"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Free Days</title>
        <description>Number of days in ICU free of ventilation</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Antifungal</title>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days</title>
          <description>Number of days in ICU free of ventilation</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="9" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Free Days</title>
        <description>Number of days free of ICU</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Antifungal</title>
          </group>
        </group_list>
        <measure>
          <title>ICU Free Days</title>
          <description>Number of days free of ICU</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="17"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibiotic Free Days 28-day Post Randomization</title>
        <description>Number of days free of antibiotic use within the first 28 days</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Antifungal</title>
          </group>
        </group_list>
        <measure>
          <title>Antibiotic Free Days 28-day Post Randomization</title>
          <description>Number of days free of antibiotic use within the first 28 days</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Measure of the duration of the participant's hospital stay</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Antifungal</title>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Measure of the duration of the participant's hospital stay</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="17" upper_limit="38"/>
                    <measurement group_id="O2" value="28" lower_limit="18" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(SOFA) Post Randomization</title>
        <description>Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure</description>
        <time_frame>post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Antifungal</title>
          </group>
        </group_list>
        <measure>
          <title>(SOFA) Post Randomization</title>
          <description>Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="3.3"/>
                    <measurement group_id="O2" value="5.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sequential Procalcitonin</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAP withCandida</title>
          </group>
          <group group_id="O2">
            <title>VAP Without Candida</title>
          </group>
        </group_list>
        <measure>
          <title>Sequential Procalcitonin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="8.8"/>
                    <measurement group_id="O2" value="22.5" spread="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAP withCandida</title>
          </group>
          <group group_id="O2">
            <title>VAP Without Candida</title>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein</title>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" spread="115"/>
                    <measurement group_id="O2" value="145.7" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin-6</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAP withCandida</title>
          </group>
          <group group_id="O2">
            <title>VAP Without Candida</title>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="183"/>
                    <measurement group_id="O2" value="3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>B-glucan Levels</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAP withCandida</title>
          </group>
          <group group_id="O2">
            <title>VAP Without Candida</title>
          </group>
        </group_list>
        <measure>
          <title>B-glucan Levels</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" spread="171"/>
                    <measurement group_id="O2" value="129.1" spread="190.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>&quot;0&quot; Total Number of Participants at Risk (e.g.., serious and other [non-serious] adverse events were not collected or assessed as part of the study).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Saline will serve as the placebo solution since the active comparator is clear and colourless.&#xD;
Normal Saline: Normal Saline</description>
        </group>
        <group group_id="E2">
          <title>Antifungal</title>
          <description>Patient will receive a dose daily for a total of 14 days&#xD;
anidulafungin: TBA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We had an overall enrolment rate/month of 0.6 patients/site for the randomized trial. Consequently, recruitment was halted prematurely despite efforts to optimize enrolment because of difficulty in recruiting patients and diminishing study resources.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Daren Heyland</name_or_title>
      <organization>CERU Queens University</organization>
      <phone>403-915-5573</phone>
      <email>dkh2@queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

